[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypersensitivity-pneumonitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypersensitivity-pneumonitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,69,94,120,150,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100578445","reimagining-interventions-for-support-and-education-in-hypersensitivity-pneumonitis-100578445",false,"NCT06811389","Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis","RISE-HP","Inclusion Criteria:\n\n* Have documented diagnosis of Hypersensitivity Pneumonitis by treating clinician.\n* Age 18 or older.\n* English Speaking.\n* Willing to work with a peer coach.\n* Have a working smart phone or tablet.\n* Have access to the internet.\n* Reside or live in the United States.\n* Endorse verbal approval from treating physician to participate in patients' goal movement\u002Fphysical activity.\n* Meet one or more of the following criteria:\n* Baseline score on the PHQ8 of \\\u003C20\n\nExclusion Criteria:\n\n* Does not have Hypersensitivity Pneumonitis\n* Younger than age 18\n* Severe cognitive impairment as determined by their treating physician.\n* Participants with severe depression (PHQ-8 score ≥20) will be ineligible for the study and will be referred to alternative sources of care.\n* Anyone with documentation in their medical chart of an eating disorder, active substance use disorder, suicidality, homicidality, acute posttraumatic stress disorder, or episodes of mania or psychosis.\n* Anyone who is determined to be severely ill or moribund by the treating clinician.","ALL","18 Years","100 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24],"NA","The central hypothesis is that a peer coach-delivered intervention that includes cognitive behavioral principles combined with theory-driven patient education will improve health-related quality of life (HRQOL) of patients with hypersensitivity pneumonitis (HP). The goal of this behavioral and educational intervention, RISE-HP, is to improve health-related quality of life in people who have hypersensitivity pneumonitis and assess feasibility and accessibility of this intervention.\n\nPatients with hypersensitivity pneumonitis (HP) experience uncertainty, feelings of anxiety and depression, and marked disruption to their lifestyle and home environment. Poor health-related quality of life (HRQOL) in HP is also driven in part by patients' profound lack of knowledge about the disease. Existing interventions for patients with HP do not target improvement in quality of life. Participants will complete either RISE-HP, a 10-session peer coach delivered behavioral and educational intervention to improve HRQOL in HP, or Staying Well, a 10-session general health education program.",[27],"Hypersensitivity Pneumonitis","RECRUITING","2026-05-26",{"date":31,"type":32},"2026-05-28","ACTUAL",{"date":34,"type":32},"2025-05-06",{"date":36,"type":21},"2026-12",{"name":38,"class":39},"Weill Medical College of Cornell University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":40},"100347151","skeletal-muscle-function-in-interstitial-lung-disease-100347151","NCT03800017","Skeletal Muscle Function in Interstitial Lung Disease","Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung Disease","Inclusion Criteria for ILD Patients:\n\n* Age 40-80 years (inclusive)\n* A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses\n* Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis\n* Appropriate candidate for pulmonary rehabilitation\n* 6 minute walk distance 50m or more\n* Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air\n* Clinically stable for the preceding 6 weeks\n* Can fluently read and write in English\n\nInclusion Criteria for Healthy Controls:\n\n* Age 40-80 (inclusive)\n* Normal pulmonary function (80-120% predicted)\n* No lung or cardiovascular disease\n* Can fluently read and write in English\n\nExclusion Criteria for the ILD patients:\n\n* Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease)\n* Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and\u002For oxygenation\n* Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25%\n* Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program\n* Use of prednisone greater than 10 mg\u002Fday for more than 2 weeks within 3 months of the first study visit\n* Significant emphysema (less than 10% volume on HRCT or FEV1\u002FFVC less than 0.70)\n\nExclusion Criteria for Healthy Controls:\n\n* Currently smoking or previously smoked more than 10 pack-years\n* Any medical conditions that prevents them for exercising safely\n* Cardiac pacemaker or any metal or electronic inside the body",true,"40 Years","80 Years",{"count":52,"type":21},40,[24],"Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.",[56,57,27,58,59],"Interstitial Lung Disease","Idiopathic Pulmonary Fibrosis","Scleroderma","Nonspecific Interstitial Pneumonia","2026-05-13",{"date":62,"type":32},"2026-05-15",{"date":64,"type":32},"2024-08-07",{"date":66,"type":21},"2026-12-31",{"name":68,"class":39},"University of British Columbia",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100609088","phase-3-randomized-controlled-trial-testing-the-efficacy-of-corticosteroid-therapy-versus-placebo-in-fibrotic-hypersensitivity-pneumonitis-100609088","NCT07210008","\"Randomized Controlled Trial Testing the Efficacy of Corticosteroid Therapy Versus Placebo in Fibrotic Hypersensitivity Pneumonitis\"","Randomized Controlled Trial Testing the Efficacy of Corticosteroid Therapy Versus Placebo in Fibrotic Hypersensitivity Pneumonitis\": RUBY Study (Randomised Trial, glUcocorticoids Versus placeBo in Fibrotic hYpersensitivity Pneumonitis)","RUBY","Inclusion Criteria:\n\n* Patient aged above 18 years and under 90 years old\n* Diagnosis of fibrotic HP (\"definite\" or \"high confidence\") after MDD according to the criteria proposed by guidelines \\[5\\]\n* Fibrosis extent ≥ 10% on chest HRCT\n* Mild to moderate functional impairment defined by FVC ≥ 50% pred and DLco ≥ 30% pred\n* Written informed consent for participation in study\n* Patient affiliated to a social security scheme or CMU beneficiary\n* Effective contraception for men and woman of childbearing age.\n\nExclusion Criteria:\n\n* Uncertain diagnosis of fibrotic HP (\"low confidence\" or \"unlikely\") after MDD according to the criteria proposed by guidelines \\[5\\].\n* Severe functional impairment defined by FVC \\\u003C 50% pred and DLco \\\u003C 30% pred.\n* Patient previously treated or currently being treated for fibrotic HP (with corticosteroids, any immunosuppressive agent, or anti- fibrotic therapies).\n* Person under guardianship\u002F curatorship (sous tutelle\u002Fcuratelle)\n* Contraindication to corticosteroid therapy (hypersensitivity to the active substances or to one of the excipients, severe infections, psychotic states not controlled by treatment, live vaccines, uncontrolled diabetes mellitus and uncontrolled arterial hypertension.) or to auxiliary medicinal products\n* Patient deprived of liberty under judicial or administrative decision\n* Patient participating in another clinical trial with an investigational medicinal product. The patient may participate in another clinical trial after the 6 months of treatment in this study\n* Pregnancy or breastfeeding woman\n* Patient receiving AME (state medical assistance)","90 Years",{"count":79,"type":21},120,[81],"PHASE3","Hypersensitivity Pneumonitis (HP) is an immune-mediated disease that manifests as interstitial lung disease after exposure to an inhaled antigen, often unidentified. HP can be classified as non-fibrotic or fibrotic HP. Fibrotic HP is associated with impaired quality of life (QoL) and reduced survival. The value and decline of forced vital capacity (FVC) are predictive factors of mortality in fibrotic HP. In most expert centres worldwide, corticosteroids are chosen as the first-line drug to treat fibrotic HP in clinical practice. However, this strategy has not been validated in a randomized controlled trial and it remains controversial, Moreover, corticosteroids are responsible for potentially serious adverse events. The hypothesis is that prednisolone, as a first-line treatment in fibrotic hypersensitivity pneumonitis (HP), slows down FVC decline compared to placebo.\n\nThe main objective is to assess the efficacy of first-line treatment with prednisolone against placebo, on the 6-month change in FVC in percent of predicted value (% pred).The primary endpoint will be the absolute change in FVC (% pred) from baseline (inclusion visit,M0) to 6 months (M6) will be compared between the placebo arm and the prednisolone arm.",[27],"NOT_YET_RECRUITING","2025-09-29",{"date":87,"type":32},"2025-10-07",{"date":89,"type":21},"2026-06-01",{"date":91,"type":21},"2028-12-01",{"name":93,"class":39},"Assistance Publique - Hôpitaux de Paris",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":40},"100469443","interstitial-lung-disease-research-unit-biobank-100469443","NCT05392881","Interstitial Lung Disease Research Unit Biobank","University of Kansas Medical Center Interstitial Lung Disease Research Unit (ILDRU) Biobank","ILDRU","Inclusion Criteria:\n\n1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)\n2. The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.\n3. The participant is ≥ 18 years of age.\n4. The participant has signed an approved consent for this study (living patients only)",{"count":103,"type":21},1000,"10 Years","OBSERVATIONAL","Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.",[56,108,57,109,27],"Sarcoidosis","Pulmonary Fibrosis",[56,108,57,109,27],"2025-09-16",{"date":113,"type":32},"2025-09-22",{"date":115,"type":32},"2021-08-09",{"date":117,"type":21},"2032-03-01",{"name":119,"class":39},"University of Kansas Medical Center",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":132,"conditions":133,"keywords":138,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":148,"locationsCount":40},"100467364","early-phase-1-fapi-pet-for-lung-fibrosis-100467364","NCT05365802","FAPI PET for Lung Fibrosis","PET Study of 68Ga-FAPi-46 in Patients With Interstitial Lung Disease: an Exploratory Biodistribution Study With Histopathology Validation.","FAPI ILD","Inclusion criteria\n\n* Patients with ILD confirmed by CT at time of staging\n* Patients who have initiated or will initiate a new ILD medication with 3 months of enrollment OR Patients who are scheduled to undergo tissue biopsy or surgery of the lung\n* Patients are ≥ 18 years old at the time of the radiotracer administration\n* Patient can provide written informed consent\n\nExclusion criteria\n\n* Patient is pregnant or nursing\n* Patients with active infectious lung disease\n* Patients not expected to comply with the protocol requirements, not able to understand or follow trial procedures",{"count":129,"type":21},30,[131],"EARLY_PHASE1","This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD).\n\nThe purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease.\n\nThe study will include patients with interstitial lung disease who have or will initiate a new ILD medication OR will undergo tissue biopsy or surgery of the lung.\n\nThe study will include 30 patients, the upper limit for PET imaging studies conducted under the Radioactive Drug Research Committee (RDRC) purview.\n\nParticipants will be injected with up to 7 mCi of 68-GaFAPi and will undergo one PET\u002FCT scan and one High Resolution CT of the lungs.\n\nThe study is sponsored by Ahmanson Translational Theranostic Division at UCLA.",[56,134,135,27,136,137,109],"Idiopathic Interstitial Pneumonias","Drug-Induced Pneumonitis","Radiation Pneumonitis","Pneumoconiosis",[139,140,141],"interstitial lung disease","pulmonary fibrosis","68Ga-FAPi-46","2025-06-30",{"date":144,"type":32},"2025-07-03",{"date":146,"type":32},"2021-11-16",{"date":36,"type":21},{"name":149,"class":39},"University of California, Los Angeles",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":160,"conditions":161,"keywords":162,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":40},"100481486","database-and-biobank-of-patients-with-hypersensitivity-pneumonitis-100481486","NCT05549635","Database and Biobank of Patients With Hypersensitivity Pneumonitis","Pulmonary Fibrosis Biobank - Hypersensitivity Pneumonitis","PFBIO-HP","Inclusion Criteria:\n\n* Diagnosis of HP at an MDT conference according to the current international guidelines\n* Age of 18 years or older\n* The patients must be capable of giving informed consent\n\nExclusion Criteria:\n\n\\- Unable to sign informed consent",{"count":159,"type":21},50,"Sub-study of the main Pulmonary Fibrosis Biomarker (PFBIO) cohort (NCT02755441), recruiting patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP). Patients are included for the collection of blood samples and regular clinical data.\n\nThe database and biobank will be available for studies of HP, and can be directly compared to the main PFBIO cohort, which has recruited patients with Idiopathic pulmonary Fibrosis (IPF) since 2016.\n\nBiomarkers will be assessed as diagnostic and prognostic. Further subtyping of HP, based on blood markers (including precipitins) will also be possible with the PFBIO-HP project.",[27],[163,164,165,166,167],"biomarker","prognosis","diagnosis","phenotyping","genotyping","2023-12-21",{"date":170,"type":32},"2023-12-22",{"date":172,"type":32},"2022-09-18",{"date":174,"type":21},"2028-12-31",{"name":176,"class":39},"Nils Hoyer",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":40},"100515202","contribution-of-the-indoor-environment-medical-advisor-in-the-management-of-fibrosing-hypersensitivity-pneumonitis-100515202","NCT05988437","Contribution of the Indoor Environment Medical Advisor in the Management of Fibrosing Hypersensitivity Pneumonitis","PHSaDom","Inclusion Criteria:\n\n* Patient of legal age,\n* French-speaking patient,\n* Patient with a diagnosis of fibrosing PHS following a multidisciplinary discussion of diffuse interstitial lung disease hypersensitivity pneumonitis .\n* Patient who had received an information note presenting the study and who had not expressed opposition to participating in this research.\n\nExclusion Criteria:\n\n* Opposition of the patient to participate in the study,\n* Patient under guardianship, curatorship or safeguard of justice,\n* Patients who have moved within the last 12 months, or who plan to move within the next 6 months,\n* Patients who have already had a visit from the indoor environment medical advisor.",{"count":185,"type":21},100,"Hypersensitivity pneumonitis (HP) is a diffuse infiltrative pneumonitis (DIP) of immuno-allergic origin, caused by exposure to one or more antigenic substances of organic origin, in genetically predisposed individuals. It can take a fibrosing form, eventually leading to chronic respiratory failure. Diagnosis is based on a combination of clinical, biological, CT scan and histological evidence, and is made during multidisciplinary discussions (MDD) of diffuse interstitial lung disease.\n\nThe antigens responsible, of domestic or professional origin, may be micro-organisms, animal proteins or chemical agents. However, the antigen remains unknown in almost 50% of cases. Lack of antigen identification is an independent risk factor for death in patients with fibrosing HP. In fibrosing forms, corticosteroid therapy does not appear to improve functional prognosis, and ninedanib, an antifibrosing treatment offered in progressive forms, only slows functional decline. Identifying the causative antigen is therefore an essential element in the overall management of these patients, with the aim of implementing avoidance measures. A medical exposure questionnaire has been translated into French to help physicians identify the antigen.\n\nThe serum precipitin assay is a tool developed to help identify sensitization to an antigen. It is all the more useful when investigations are targeted at the patient's suspected exposure. However, their sensitivity and specificity are variable.\n\nThe activity of the indoor environment medical advisor (CMEI) has developed in the care of patients with chronic respiratory or allergic pathologies. Their role is to carry out an audit of the dwelling, take environmental measurements to assess the health risk, inform patients about appropriate eviction measures and, in some cases, refer patients to organizations specializing in home improvement.\n\nThe CMEI visits the patient's home. The environmental audit includes a rigorous macroscopic examination and microbiological swabs of visible anomalies. The CMEI can also supplement its analysis with electrostatic dust collectors, which are left in the home for 4 weeks, enabling both qualitative and quantitative characterization of antigens.\n\nTo date, no study has prospectively evaluated the contribution of CMEI to antigen identification in patients with fibrosing HP. At the Nantes University Hospital and Angers University Hospital, the environmental audit carried out by the CMEI is an integral part of routine patient management in the event of a HP diagnosis.\n\nThe main objective of this study is to measure the diagnostic contribution of the indoor environment medical advisor in the identification of antigens responsible for respiratory pathology in patients with fibrosing HP.",[27],[189,190],"Fibrosing","indoor environment medical advisor","2023-09-25",{"date":193,"type":32},"2023-09-28",{"date":195,"type":21},"2023-12-12",{"date":197,"type":21},"2026-06-12",{"name":199,"class":39},"Nantes University Hospital"]